Giananthony Rizzo[email protected]Nuclear MedicineIs the U.S. due for a shortage of SPECT tracers? Part 2In the second part of our series on the coming shortage of SPECT radiopharmaceuticals, Giananthony Rizzo of Decision Resources Group examines other factors in the U.S. healthcare industry that could affect isotope prices in the future.November 17, 2016Nuclear MedicineIs the U.S. due for a shortage of SPECT tracers? Part 1A perfect storm is brewing in the global SPECT market that could see the prices of radiopharmaceuticals skyrocket over the next five years. A number of factors are coalescing that could lead to a shortage of SPECT tracers for years to come, according to this article by Giananthony Rizzo of Decision Resources Group.November 16, 2016Page 1 of 1Top StoriesRadiation Oncology/TherapyStudy highlights value of radiologist involvement in RT planningRadiologist peer review improves the rate of clinically meaningful changes to radiation therapy (RT) planning, researchers have reported.CTThe challenges of dysrhythmic radiologistsBreastWomen with BRCA1/2 germline mutations are often denied breast MRIWomens ImagingStarting breast cancer screening at 40 is more cost-effectiveMolecular ImagingPSMA-PET/CT bests conventional imaging for prostate cancer diagnosis
